Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Wolf, P; Nghiem, DX; Walterscheid, JP; Byrne, S; Matsumura, Y; Matsumura, Y; Bucana, C; Ananthaswamy, HN; Ullrich, SE.
Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis.
AMER J PATHOL. 2006; 169(3): 795-805.
Doi: 10.1253/ajpath.2006.060079
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Wolf Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Psoralen plus UVA (PUVA) is used as a very effective treatment modality for various diseases, including psoriasis and cutaneous T-cell lymphoma. PUVA-induced immune suppression and/or apoptosis are thought to be responsible for the therapeutic action. However, the molecular mechanisms by which PUVA acts are not well understood. We have previously identified platelet-activating factor (PAF), a potent phospholipid mediator, as a crucial substance triggering ultraviolet B radiation-induced immune suppression. In this study, we used PAF receptor knockout mice, a selective PAF receptor antagonist, a COX-2 inhibitor (presumably blocking downstream effects of PAF), and PAF-like molecules to test the role of PAF receptor binding in PUVA treatment. We found that activation of the PAF pathway is crucial for PUVA-induced immune suppression (as measured by suppression of delayed type hypersensitivity to Candida albicans) and that it plays a role in skin inflammation and apoptosis. Downstream of PAF, interleukin-10 was involved in PUVA-induced immune suppression but not inflammation. Better understanding of PUVA's mechanisms may offer the opportunity to dissect the therapeutic from the detrimental (ie, carcinogenic) effects and/or to develop new drugs (eg, using the PAF pathway) that act like PUVA but have fewer side effects.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Apoptosis - drug effects
- Candida albicans - immunology
- Candidiasis - drug therapy
- Combined Modality Therapy - methods
- Female - methods
- Ficusin - pharmacology
- Humans - pharmacology
- Hypersensitivity, Delayed - drug therapy
- Immune Tolerance - drug effects
- Immunosuppression - methods
- Inflammation - drug therapy
- Interleukin-10 - immunology
- Lymphoma, T-Cell, Cutaneous - drug therapy
- Male - drug therapy
- Mice - drug therapy
- Mice, Knockout - drug therapy
- PUVA Therapy - adverse effects
- Platelet Activating Factor - immunology
- Platelet Membrane Glycoproteins - deficiency
- Psoriasis - drug therapy
- Receptors, G-Protein-Coupled - deficiency
- Signal Transduction - drug effects